Comprehensive Strategic Analysis: Pharmaceutical Trademarks in Brazil (RPI 2829 Insights)

Subtitle: *Navigating Innovation, Competition, and Regulatory Shifts in PharmaIP*

- **Date:** "March 25, 2025"
- **Contact Information:** "M. J. Zanon – Brazilian IP Attorney-At-Law
- Consultant & Registered Patent Agent, Email: iplawyer@mjzanon.com

Prepared by: M. J. Zanon – Brazilian IP Attorney-At-Law
Consultant & Registered Patent Agent
Email: iplawyer@mjzanon.com
Website: http://www.mjzanon.com

Executive Summary

RPI 2829 (March 25, 2025) highlights a surge of intellectual property activity in Brazil's pharmaceutical, biotech, and health-tech sectors.

A high volume of trademark filings, focused in health and tech classes, reflects intense brand development in pharma, nutraceuticals, and healthcare services.

Simultaneously, major pharmaceutical patents – largely from global players – entered the national phase, targeting therapeutic areas like autoimmune disorders, metabolic diseases, and rare genetic conditions. Numerous health-tech software registrations by companies, research institutions, and startups signal a robust push toward digital health solutions.

Key themes include the **convergence of technology and healthcare** (e.g. telehealth platforms, AI-powered health tools) and **cross-sector moves** (cosmetics and fintech firms branching into health) Collectively, these filings suggest that stakeholders are positioning for a **digitally enhanced healthcare market**, with companies securing IP across drugs, wellness products, and supporting software. The strategic implications point to emerging opportunities in telemedicine, AI-driven health services, and gaps in local pharma innovation, against a backdrop of intensifying competition in Brazil's health-related industries.

1. Trademark Activity Overview

Volume and Top Filers: Trademark filings in pharma, biotech, and health-tech classes were vigorous in RPI 2829. Leading filers this edition were dominated by wellness and healthcare companies, marking a shift from traditional pharma dominance. Notably, a **nutritional supplements company** topped the list with 15 applications, closely followed by a major **cosmetics & personal care firm** with 14 filings.

A prominent **domestic pharmaceutical manufacturer** filed 12 marks, signaling a broad pipeline of new products. Other significant filers included a large **healthcare provider network** (~8 filings) and even an affiliate of a global luxury/cosmetics group (~9 filings) expanding into supplements. This mix underscores that competition is not just among drug makers – **supplement brands and health service providers are aggressively securing brands**, outpacing some big pharma firms in sheer filing count.

Filing Trends by Class and Region: The filings heavily concentrated in **Class 42 (technology services)** and **Class 44 (medical and health services)**, alongside Class 5 (pharmaceuticals) and Class 10 (medical devices), reflecting the blending of tech and healthcare in branding. Class 42's prominence indicates companies positioning in health-tech offerings (e.g. digital platforms, telehealth apps), while Class 44's volume shows sustained activity in medical services and wellness clinics. In terms of geography, the **Southeast region dominates** – São Paulo (SP) remains the hub for filings, followed by Minas Gerais (MG) and Paraná (PR). This mirrors Brazil's industrial and healthcare center of gravity. Notably, Santa Catarina (SC) showed gradual growth as an emerging cluster, though the overall regional distribution saw no radical shifts in this period. Companies can thus anticipate that competitive brand activity will be heaviest along the SP/MG/PR corridor, with secondary hubs slowly gaining traction.

Noteworthy Entrants and Spikes: The trademark data reveal **new and cross-sector players** entering the health space. For example, a leading private hospital/insurance group (Hapvida) featured among top filers, indicating that healthcare providers are investing in brand differentiation for services (likely in response to telemedicine competition). A surprising entrant was an international luxury/cosmetics affiliate (Tradal Brazil) filing a suite of **nutricosmetic and supplement marks**, signaling diversification from beauty into wellness. Such moves highlight a blurring of industry lines – companies traditionally outside

core pharma are now vying for space in health and wellness. Meanwhile, some big pharma names (e.g. **Aché, Blau Farmacêutica**) were present but with fewer filings this round. The fact that mid-sized and non-traditional health companies took the lead in filings suggests a "spike" in activity for nutraceuticals and health services. It also implies a defensive strategy: firms are quickly securing portfolios of related marks (brand families) around health trends like plant-based supplements ("Vegan") and aesthetic clinics, to preempt competitors. In summary, Brazil's trademark landscape this period shows a **broadening base of players** – from pharma to fintech-backed health platforms – all staking their brand claims in an increasingly integrated health-tech market.

2. Patent Filing Analysis

Active Patent Filers (Pharma/Biotech): Patent publications in RPI 2829 underscore strong activity by **international pharmaceutical companies**, with a focus on Brazil's national phase entries for PCT applications. Several high-profile filers include:

- **Novartis AG (CH)** – filed patents on **biaryl YAP/TAZ-TEAD protein-protein interaction inhibitors**, likely for cancer or fibrosis therapy (crystalline form innovations). This indicates Novartis' strategic investment in advanced oncology/immunology compounds in the Brazilian market.
- **F. Hoffmann-La Roche AG (CH)** – filed patents for **novel pyrazolo[3,4-b]pyridine compounds to treat autoimmune diseases**. Roche's filings in Brazil signal an effort to secure rights for potential future drugs (e.g. immunosuppressants), aligning with its global pipeline in immunology.
- **Alebund Pharmaceuticals (HK/CN)** – secured a patent for **"compostos deuterados" (deuterated compounds)** aimed at metabolic and cardiovascular disorders. The CPC classifications (e.g. A61P 3/10 for glycemic control, A61P 9/00 for cardiac therapy) suggest these compounds target diabetes and related conditions, a growing market in Brazil.
- **Ractigen Therapeutics (CN)** – filed an application on **oligonucleotide modulators that upregulate utrophin**, which is a cutting-edge approach for Duchenne Muscular Dystrophy (a rare disease). This indicates Chinese biotech interest in bringing advanced gene therapies or RNA-based treatments to Brazil.

Notably, **domestic Brazilian companies are less visible** in this patent batch – the lion's share of pharma/biotech patent filings came from foreign firms via PCT national-phase entries. This reflects that multinational players and overseas biotechs are actively securing IP for new therapies in Brazil, whereas local pharma innovators did not show prominently in this particular edition.

CPC Classifications & Therapeutic Focus: The patent CPC codes reveal a **concentrated focus on certain therapeutic areas and technologies**. Many filings fall under A61K/A61P codes, indicating pharmaceuticals for specific diseases. For instance, multiple patents were classified in **A61P 37/00**, covering drugs for immune system disorders (including autoimmune diseases). Others had codes like **A61P 3/10** (metabolic disorders, e.g. anti-diabetics) and **A61P 9/00** (cardiovascular), or **A61P 21/00** (muscular disorders) for the Duchenne therapy. The presence of **biotechnology-related codes** is also notable: e.g. C07K 16/00 for antibodies or peptides and C12N/C12Q codes for nucleic-acid based inventions. This suggests a trend towards biologics and gene therapies. In summary, the patents indicate strong innovation in **immunology, metabolic disease, and rare genetic conditions**, aligning with global pharma R&D priorities. Absent in this set are, for example, straightforward antibiotics or basic generics – the focus is on cutting-edge or specialized treatments.

Competitive Implications: The patent filings carry several strategic signals. Firstly, the **commitment of global firms like Novartis and Roche to secure Brazilian patents** implies that Brazil is a key market in their long-term plans for these new therapies. We can anticipate that these companies are laying groundwork to introduce advanced drugs (for cancer, autoimmune diseases, etc.) into the Brazilian market in coming years, potentially altering the competitive treatment landscape. For local pharmaceutical companies, this raises the stakes – they will soon face competition from new patented therapies or will need to seek partnerships/licensing to stay in the game. Secondly, the **diversity of countries of origin** (Switzerland, China, Hong Kong) for these filings shows a broad international interest in Brazil's pharma sector. Emerging market biotechs (e.g. Ractigen, Alebund) are looking at Brazil early, not just the established US/EU/Japanese players. This could increase competitive pressure on domestic players but also create opportunities for collaboration (such as conducting clinical trials or co-developing products locally). Lastly, the **technology focus** (e.g. RNA therapies, targeted biologics) suggests that competition will extend beyond traditional small-molecule drugs into high-tech therapeutics. Brazilian regulators and healthcare providers may need to prepare for these complex therapies (in terms of evaluation, approval, and eventually

market adoption). From a defensive standpoint, companies with overlapping research might rush to file their own patents or adjust their portfolios to avoid being blocked in Brazil. Overall, the patent activity in RPI 2829 serves as a **forward-looking indicator of competitive shifts** – with global innovation making inroads, companies will need to innovate or strategize accordingly to maintain their market positions.

3. Health-Tech Software Registration Insights

Key Registrants and Solutions: The RPI 2829 bulletin's computer program registrations (software) reveal a vibrant scene of health-tech innovations, involving players from small startups to large institutions. Several notable health-related software registrations include:

- **"Clínicas Integradas"** – a software by a small enterprise (Randal Gasparini ME) aimed at integrated clinic management. Its registration details show a broad scope (application fields *SD-01 through SD-11*, covering various healthcare service categories) and a diverse tech stack (developed with AJAX/Delphi, HTML/JS, MySQL, PHP, etc.). This suggests a comprehensive platform for healthcare providers, possibly managing patient records, appointments, billing, and telehealth, with even some **AI components** (the program type includes IA-01/02, indicating artificial intelligence features).
- **"ANCLINIC APP"** – a mobile or web application registered by independent developers (Paulo R. Santiago and Pedro H. M. Nachabe) for clinic services (). It appears oriented toward patient-clinic interaction or telemedicine (fields listed include SD-01, SD-02, SD-06, SD-07, which likely correspond to various healthcare and telehealth sub-domains. This reflects how individual entrepreneurs are creating solutions for online consultations, medical scheduling, or patient engagement.
- **"IPD Saúde"** – a program by **Servir Participações Ltda**, presumably a healthcare company or investor, focusing on health ("Saúde"). While details on its function are scant in the listing, the corporate backing and registration point to an initiative in digital health services, possibly an platform for integrated care or insurance-related health management.
- **"VisCalc"** – titled *"Software para Análise da Relação entre Escore VIS, Tempo de Ventilação Mecânica e Internação Hospitalar"*, this tool is clearly a specialized healthcare analytics software. Developed by medical researchers (J.C.B. Baranauskas, P.V. Eckel Moreira, et al.),

VisCalc is used for analyzing intensive care unit parameters (Vasoactive Inotropic Score, ventilation time, hospital stay) – essentially a clinical decision support or research tool. Technologically, it's built with modern languages (CSS/HTML/JavaScript, NodeJS, JSON, PostgreSQL) for web-based data analysis, underlining how clinicians are leveraging software to improve care outcomes.

In addition to these, other registered programs of note came from **academic institutions**. For example, the **Federal University of São Carlos (UFSCar)** registered a "software for contactless temperature measurement" – likely a public health or biomedical engineering project useful for fever screening. The **University of Brasília (UnB)** also registered research software (e.g. "CRSIDLab 3.0"), which, given its classification under an SD (health-related) field, might be related to some health data analysis or simulation in medical research.

Software Purpose & Tech Stacks: A clear pattern is that these software solutions target **healthcare delivery, management, and analytics**. Many aim to streamline clinical workflows (clinic management apps), enhance patient engagement (mobile health apps), or process medical data (ICU analytics, telemedicine platforms). The **tech stacks** tend toward widely-used, open-source technologies – e.g. systems built with Python, JavaScript (Node.js, JSON), PHP, .NET, and database languages like SQL. This indicates that developers are choosing mature technologies to ensure reliability and faster development for healthcare applications. Legacy technologies like Delphi and Pascal appear in one case, showing that even older systems (perhaps an evolution of long-standing clinic software) are being formally registered now as companies modernize their solutions. On the other end, the presence of **AI modules** (seen in program classification codes IA-01, etc.) suggests some applications include machine learning or intelligent features – for instance, predictive analytics for patient outcomes, or AI-driven chatbots for patient inquiries. The inclusion of **multiple application fields (SD codes)** under a single software indicates that many solutions are multi-functional – e.g. an app might handle telemedicine (SD-07), electronic health records (SD-06), and health administration (SD-01) all in one. This holistic approach aligns with the needs of an integrated digital healthcare ecosystem.

Regulatory Relevance: Registering software with the INPI, while not mandatory for copyright, can be strategically significant, especially in healthcare. Developers and companies may be securing registrations to

establish **proof of creation/ownership**, which can be useful in compliance audits and partnerships. Healthcare software often deals with sensitive patient data and operates under regulations like Brazil's data protection law (LGPD) and telehealth guidelines. For example, an app facilitating **medical consultations or advice** (as indicated by descriptions like "consultas médicas; assistência médica" in some trademark specs) directly intersects with telemedicine regulations that were recently made more flexible. The flurry of health app registrations suggests that companies are gearing up to offer such services in compliance with legal frameworks. Moreover, the **convergence of health and fintech** noted in trademarks (e.g. a bank registering a health platform brand) also manifests in software: one can imagine integration of payment systems into health apps or insurance-tech platforms. **Public institution involvement** (like UFSCar's temperature monitoring tool) also hints at support for public health initiatives – these could be tools used in hospitals or by health authorities, where formal registration bolsters trust and official adoption. In summary, the software registrations paint a picture of a health-tech sector preparing for **scaled deployment**, ensuring their innovations are both protected and positioned to meet regulatory and market expectations (for instance, by securing their IP and demonstrating technological capabilities in AI or data management, which are hot topics for regulators and investors alike).

4. Technology/Classification Overview

Convergence of Technologies and Domains: The combined view of trademarks, patents, and software from RPI 2829 reveals a clear **convergence between healthcare and technology** on multiple fronts. Trademark classes and software fields show overlapping focuses – *Class 42* filings and software with "SD" (health) application fields both underscore how digital tech and healthcare services are intertwined. For example, many healthcare providers are branding their telehealth platforms and simultaneously those platforms are being developed and registered as software. On the patent side, while the technologies differ (pharmaceutical molecules vs. software code), there is a thematic alignment: patents protect the **therapeutic innovations** (new drugs, biologics) while trademarks and software protect the **delivery mechanisms and patient-facing innovations** (brands for services, digital tools for care). This suggests that the overall strategic intent of organizations in this space is to create **integrated solutions** – not just a drug, but a drug plus a companion app; not just a clinic, but a clinic with proprietary software and a strong brand.

CPC Codes vs. Software Tech: Interestingly, the CPC classifications in pharma patents can be juxtaposed with the nature of health software to map out strategic focus areas. The patents largely cluster in **biotech and pharma classifications** (e.g. A61K/A61P for pharmaceuticals, C07K for peptides/antibodies, C12N for genetic tech) – indicating innovation in the **biological and chemical domain**. The software, on the other hand, involves classifications like GI (management information), AP (applications), and notably **IA (artificial intelligence) for some health programs**. This reflects innovation in the **digital domain** of healthcare. When mapped together, one can see complementary efforts: e.g., an autoimmune drug patent (biotech) might eventually be complemented by a companion diagnostic app or an AI that helps identify patients for that therapy. Indeed, some of the software fields (SD-05, SD-06 etc.) could correspond to health data analysis, which aligns with precision medicine trends seen in pharma. There's also a trend of **"digital therapeutics"** emerging globally – while not explicitly labeled here, the groundwork is visible: pharmaceuticals are being developed alongside digital health management tools. The **AI-driven mapping of strategic intent** would likely highlight clusters such as *immunology* (patents for immune diseases + many "Saúde" brands + software for chronic disease management) and *telehealth/remote care* (trademarks for online health services + software for clinics/patients). Financial tech integration is another cluster: for instance, a bank's trademark for a health signals convergence of fintech and health-tech, possibly in insurance or health financing solutions.

Sector Convergence and Strategic Intent: There is a noticeable **sector convergence** underway – companies traditionally in separate domains are finding common strategic ground in health-tech. Trademarks show cosmetic and wellness companies entering the healthcare market (e.g., a cosmetics giant filing health service trademarks, a luxury goods firm registering supplement brands). In parallel, tech companies and even financial institutions are creating health-focused products (software or platforms) to capture part of the healthcare value chain. The presence of AI in health software and "smart" terminology in branding indicates that automation and intelligence are becoming standard expectations in healthcare offerings. From a bird's-eye view, these patterns suggest that **strategic intent is oriented towards integrated, data-driven healthcare solutions**. A healthcare provider isn't just a hospital now – it's a hospital with a telemedicine app, AI triage, and an ecosystem of wellness offerings under a unified brand. A pharma company isn't just launching a pill – it's perhaps envisioning a combination of therapy + digital support (for adherence, for patient monitoring, etc.). The data from RPI 2829, when

interpreted collectively, paints a picture of an industry aiming to provide end-to-end solutions: medicines *plus* services *plus* software, all protected through IP. This convergence is blurring the lines between pharma, biotech, tech, and consumer wellness sectors. For instance, an insurance or hospital group's filings indicate they want to be seen not just as care providers but also tech providers. Likewise, pharma firms filing in Class 42 or 44 for companion services shows they intend to play in the service delivery space, not just supply drugs. **AI-driven analysis** of these trends would likely conclude that companies are hedging their bets by building multidisciplinary portfolios – to capture patients' entire journey (prevention, treatment, after-care) and to create defensible positions as healthcare becomes more digital.

5. Strategic Implications and Forecasts

White Spaces and Opportunity Zones: Despite the broad coverage of filings, the data hints at certain *white spaces* in the Brazilian IP landscape for health. One noticeable gap is the relative scarcity of **domestic-origin pharmaceutical patents** – an opportunity exists for Brazilian companies or research institutions to step up R&D in key areas like biologics or novel small molecules. With global players bringing advanced therapies (e.g. in autoimmunity and genetic diseases), local entities could focus on complementary niches such as **tropical diseases, affordable biosimilars, or adjunct digital therapeutics**, where fewer filings are seen. In trademarks, while wellness and telehealth are heavily filed, areas like **mental health services or digital therapeutics branding** might be underrepresented – this could be a whitespace for new startups specializing in mental health apps or therapy platforms to establish brand presence. Similarly, among software, we see many clinical management and telemedicine tools, but not much explicitly on, say, **health data analytics platforms for research** or **patient wearables integration** – suggesting potential for growth in health AI analytics or IoT health device software that are not yet mainstream in filings. **Preventive healthcare** is another zone: many trademarks emphasize treatment or wellness, but there may be room for more IP around prevention tech (e.g. screening AI, lifestyle management programs). Companies scanning the horizon can look to these gaps as potential opportunity zones where competition is currently lighter.

Competitive Signals: The filings in RPI 2829 send strong competitive signals. The **aggressive trademark activity by supplement and cosmetic companies** indicates that traditional pharma companies will face increased

competition from consumer-health and wellness brands in Brazil. For example, a supplement company leading trademark filings suggests that the nutraceutical market is heating up – pharma firms may need to respond by either entering that segment or emphasizing the pharmaceutical rigor of their products to differentiate. The **entry of Hapvida (a major HMO)** into top filers () signals that integrated healthcare providers are fortifying their brand portfolios, likely to protect their turf in a future where telehealth and nationwide clinic networks compete for patients. This is a cue to other healthcare groups (e.g., Unimed, SulAmérica) that brand and technology will be key to retaining patient loyalty. On the patent side, the presence of multiple Chinese biotechs (Ractigen, Alebund, Hangzhou mentioned in filings) shows an eastward shift in innovation sources – Brazilian and Western pharma companies should watch these entrants as new competitors who might bring cost-competitive and innovative approaches. Also, **Novartis and Roche's patent moves** serve as a warning to domestic companies that global heavyweights are securing positions in next-gen therapies in Brazil. We can infer that if, say, Roche is patenting an autoimmune drug, they likely plan to launch it in Brazil; competitors in immunology (like AbbVie, for instance) might need to prepare by accelerating their own filings or marketing strategies in that therapeutic area. The **cross-sector filings** (e.g., a financial institution's health platform trademark) signal to pure-play health companies that competition can come from unexpected directions – a bank or tech giant could become a healthcare delivery player through digital means. This implies that incumbents should build partnerships or capabilities outside their traditional domain (for example, a hospital partnering with a fintech for health payments, or a pharma company collaborating with a tech firm for digital adherence tools) to pre-empt disruption. In sum, the competitive intelligence gleaned from these filings is that **the battlefield is expanding**: it's not just pharma vs pharma or hospital vs hospital, but an ecosystem fight involving tech, finance, consumer goods, and foreign entrants – all converging on the health market.

Innovation Alignment and Market Readiness: The alignment of these filings with broader trends suggests that Brazil's market is gearing up for cutting-edge healthcare innovation – and, importantly, appears **ready to absorb it**. The heavy use of terms like "Saúde", "Clínica", "Digital" and even "AI" in trademarks mirrors global trends of digital health and smart healthcare services, indicating that companies believe Brazilian consumers are receptive to high-tech health solutions. The patent filings in areas like immunotherapy, gene therapy, and precision medicine imply that the scientific and regulatory environment in Brazil is conducive enough to justify seeking patent protection (e.g., ANVISA's

evolving stance on advanced therapies, or incentives for innovation). In software, the multitude of health apps and platforms being registered shows that the healthcare system is embracing digital transformation (from electronic records to telehealth) – a sign of market readiness accelerated perhaps by the pandemic experience. Government moves, such as the telemedicine legalization and data protection law implementation, have likely laid the groundwork, and now the filings demonstrate companies executing on those new possibilities.

We see **innovation alignment** in that many filings resonate with global health priorities: wellness and preventative care (trademark trends), personalized medicine (patent targets like YAP/TAZ, utrophin), and healthcare accessibility via tech (software for remote care). Moreover, the synergy between filings – e.g., a therapeutic patent and a related service trademark – suggests a holistic approach to market entry, which is often only viable if the market is ready for it. For instance, a few years ago a telehealth app might not gain traction, but now multiple telehealth solutions are being branded and protected, implying that patients are starting to use these services widely.

Therefore, we forecast an **accelerating rollout of innovative healthcare products and services in Brazil** in the short to mid term. Companies have their IP ready, so the next steps likely involve product launches, clinical trials, and commercialization efforts. We anticipate seeing more collaborations between pharma and tech (to combine treatment + tech support), a rise in **“phygital” health services** (physical-digital hybrid offerings like app-connected clinics), and an ongoing diversification of players in the market. The **market is primed**, and those who have aligned their innovations with these trends (and protected them through IP, as seen in RPI 2829) will be positioned to lead the upcoming wave of healthcare transformation in Brazil. The data from this bulletin essentially serve as a precursor to that evolution – showing who is gearing up in what way – and it points to a Brazilian healthcare sector on the cusp of significant tech-driven growth, increased competition, and improved solutions for patients.

TRADEMARKS: Introduction & Key Highlights from RPI2829, published on25/03/2025.

Pharmaceutical trademark activity in Brazil continues at a vigorous pace in **RPI 2829** (25/03/2025). This latest Industrial Property Bulletin reveals a **high volume of new filings** across pharmaceutical, biotech, and healthcare sectors, reflecting strong industry growth and increasing market competition. Notably, the rise of **technology-driven filings** under Class 42 signals a growing overlap between pharmaceutical and tech sectors. Financial and fintech firms, such as **Banco Rendimento**, have started registering trademarks for technology-based platforms that could support healthcare services, highlighting the increasing integration of health-tech and financial solutions. The competitive landscape remains intense, with established pharma companies and emerging players actively filing to secure brand positions. This report provides a detailed analysis of recent filings, opposition trends, and competitive signals, offering strategic insights for pharmaceutical companies to navigate Brazil's evolving IP environment.

Filing Trends & Brand Themes



Figure 1: Word Cloud of Trademark Names (RPI 2829). The dominant themes in recent pharma-sector trademarks strongly emphasize **health, wellness, and beauty**. Terms like "**Saúde**" (health) and "**Clínica**" (clinic) appear prominently, underscoring the core focus on medical services. Similarly, words such as "**Estética**" (aesthetics) and "**Beauty**" stand out, reflecting robust activity in cosmetic dermatology and personal care branding. Notably, this edition sees increased visibility of **holistic and lifestyle-oriented terms** – for example, "**Vegan**" surfaces as a keyword in new supplement trademarks, hinting at the rising trend of natural and plant-based health products. Traditional pharma-related terms remain prominent too: "**Farmácia**" (pharmacy), "**Instituto**" (institute), and "**Laboratório**" (laboratory) continue to feature frequently, indicating many brands associated with clinics, research labs, and medical institutes.

Technology influences also persist in branding. Even in the pharma domain, **digital and "smart" terminology** is present alongside medical terms. For instance, one new mark references "**AI Powered**" services, aligning with the broader telehealth and healthtech movement. Terms like "**Inteligente**" (intelligent) and "**Digital**" appeared in prior data and continue to be relevant, confirming that the **convergence of tech and healthcare** is a key narrative in branding strategy. The word cloud suggests companies are often using compound names combining wellness or beauty terms with tech or efficiency-oriented words (e.g., "+Tech", "Smart", "Fit"), mirroring the integration of technology into healthcare solutions.

Another insight from the branding patterns is the practice of **defensive filings** and brand families. The repetition of certain words across multiple filings hints that firms are securing series of marks around a common root or theme. Leading companies frequently file **multiple related trademarks** (for example, a line of supplement products all containing "Gummy" or a series of cosmetics under a shared brand prefix. This indicates a strategy to **build brand families** and **preempt imitations**, guarding their market space by covering variations of a flagship name. In summary, the language of RPI 2829's trademarks underscores a market still centered on health and wellness concepts, now augmented by lifestyle (e.g. vegan, fitness) and tech-driven keywords. Companies are branding not just for today's pharmaceuticals, but for a future of integrated health-tech services and holistic wellness products.

Regional Filing Patterns



Figure 2: Trademark Filings by State – RPI 2829 (25/03/2025). The geographic distribution of pharma-related filings in Brazil remains **highly concentrated in the South and Southeast**, following historical trends. **São Paulo (SP)** once again dominates as the origin of the most filings – on the order of roughly one-third of all new trademarks originate from SP-based applicants, reaffirming São Paulo's role as the nation's commercial and innovation hub for pharmaceuticals.

This share is in line with the previous bulletin (SP had ~32% in RPI 2828) and reflects the dense cluster of pharma companies, startups, and research institutions in greater São Paulo.

Minas Gerais (MG) and **Paraná (PR)** continue to hold their ranks as the second and third most active states, respectively. MG's contribution (on the order of 10–12% of filings) remains robust, supported by the growing pharmaceutical and biotech scene around Belo Horizonte. PR follows with roughly 8–9% of filings, maintaining a strong presence (particularly with niches like agritech and cannabis-derived pharma in cities such as Curitiba and Maringá, as noted previously. An important regional development is the role of **Santa Catarina (SC)**. In the last

report, SC emerged nearly on par with Rio de Janeiro in filing volume. In RPI 2829, **SC has essentially matched (or slightly exceeded) Rio de Janeiro (RJ)** in new pharma trademark filings, with each state contributing around 8–9% of the total. SC's continued rise is driven by its growing biotech and medical device startups in hubs like Florianópolis and Joinville, which are increasingly active in securing trademarks. **Rio de Janeiro (RJ)**, home to major pharma companies' offices and institutes (e.g., Fiocruz), maintains a steady output of new filings (roughly mid-single-digit percentage of the total). RJ's stable share suggests a consistent rate of trademark activity, neither spiking nor dropping significantly – likely reflecting ongoing projects in big pharma and healthcare institutions in the state.

Outside the top five states, **Rio Grande do Sul (RS)**, **Goiás (GO)**, and **Bahia (BA)** each account for a modest share of filings, generally in the few dozen applications each.

These states remain important regional contributors: for example, RS hosts pharma manufacturers in Porto Alegre and surroundings, GO has a growing generic pharma industry, and BA sees activity around the Salvador area. Collectively, however, the Northern and Northeastern states still represent a relatively small fraction (under ~15% combined) of the country's pharma trademark filings – a pattern consistent with long-standing imbalances in Brazil's innovation ecosystem.

The takeaway is that **geographical dynamics in RPI 2829 show continuity** with prior trends: Brazil's pharma trademark filings are concentrated in established industrial centers, with gradual growth in secondary hubs like Santa Catarina, but no radical shifts in one week. This geographic stability means companies can predict where domestic competition is most likely to emerge (SP/MG/PR corridors), even as they should note the incremental rise of emerging clusters (like SC) as future competitive hotspots.

Competitive Landscape & KLey Players

Top Trademark Filers – RPI 2829



Figure 3: Top Trademark Filers – Pharma/Health Sector (RPI 2829). A look at the top filers of trademarks in this edition reveals some **notable shifts in the competitive landscape**. In RPI 2828, a mid-sized pharma company (Blau Farmacêutica) surprised the industry by leaping to the forefront with 13 filings.

In RPI 2829, the leadership has rotated: a **dietary supplements company, BS Suplementos Ltda., leads with 15 new applications**, the highest by any single applicant this round. BS Suplementos' filings (covering brands like "Whet Vegan", "Skin On Plus", "Full", "Owl", etc.) underscore the booming supplements and nutrition segment and suggest an aggressive brand expansion in that space. Close behind is **O Boticário Produtos de Beleza Ltda.**, a major cosmetics and personal care company, with 14 filings. Boticário's strong showing (up from its activity in

prior weeks) indicates that the beauty and wellness sector continues to interlace with pharmaceuticals – many trademark filings from Boticário likely relate to Class 3 cosmetics or Class 44 aesthetic services, which complement healthcare trends (e.g., dermocosmetics and clinic franchises).

Among pure pharmaceutical players, **A2F Indústria Farmacêutica Ltda.** stands out with 12 filings. A2F is a domestic pharma manufacturer, and its high filing count suggests a broad pipeline of new products or a strategy to solidify its brand portfolio across multiple drugs. Indeed, A2F's multiple trademark applications in this bulletin signal an assertive push – possibly covering new medications, line extensions, or even some defensive registrations in anticipation of future product launches. This shows mid-sized pharma firms are actively **scaling up IP protection**, not leaving the branding arena only to the biggest multinationals.

Also notable is the presence of **Hapvida Assistência Médica Ltda.** with around 8 filings. Hapvida is one of Brazil's largest healthcare providers (hospital and insurance network), and its trademark activity likely covers new health services, plans, or digital platforms. Its inclusion in the top filers underscores how **health service companies are investing in brand differentiation**, likely responding to increased competition in telemedicine and integrated care services.

It's worth mentioning **Tradal Brazil Comércio, Importações e Exportações Ltda.** with 9 filings. Tradal is affiliated with international brands (known to manage trademarks for luxury goods and cosmetics, possibly part of the LVMH group's local operations). Their filings in this edition include a series of **nutricosmetics and supplement names** (e.g., "Her Beauty Gummy", "Calm Gaba", "Glutationa")

– indicating that global players are expanding into Brazil's wellness supplement market. This cross-sector participation (a luxury/cosmetics house moving into nutritional supplements) highlights a trend of **diversification**, where companies outside traditional pharma seek a foothold in health and wellness segments.

Meanwhile, some **traditional big pharma names are present but less dominant** this week. For example, **Aché Laboratórios Farmacêuticos S.A.** filed at least one new mark ("Osteon"), and **Blau Farmacêutica S.A.** filed a couple (e.g., "Zubeva"), but neither approached the top of the chart this time. This contrasts with the previous bulletin where those firms were front-runners. The absence of a large multinational like Roche or Pfizer from the top-filer list suggests that **global pharma companies had a quieter week in terms of quantity of filings**, although they remain consistently active over longer periods. It's not unusual for big pharma to file in spurts timed with product development cycles, so a one-week dip is not indicative of reduced interest—rather, we continue to see steady, strategic filings by these players (just not a bulk spike in this particular issue).

Banco Rendimento's Trademark Activity in Class 42

"Class 42 covers technological and software-based services, which have growing relevance to healthcare and pharmaceutical platforms (e.g., telehealth and payment gateways)."

An unexpected entrant in the pharmaceutical trademark dataset is Banco Rendimento S.A., which filed multiple trademarks under Class 42 – covering technology-based services such as software platforms and financial services. The registered marks, including "Rendcâmbio" and "Rendimentocâmbio," suggest that Banco Rendimento is securing brand protection for platforms related to financial and exchange services. While not directly pharmaceutical, these filings align with a broader trend of financial institutions entering adjacent healthcare and technology sectors. For example, Class 42 filings for fintech platforms that support healthcare transactions (e.g., payment gateways for telehealth services or insurance claim processing) have been increasing. Banco Rendimento's strategic positioning in Class 42 indicates that financial and technology-based services are becoming more integrated with healthcare solutions, highlighting the convergence between the financial and health-tech sectors. This underscores the growing need for pharmaceutical companies to monitor cross-sector trademark activity, as fintech and healthcare innovations increasingly intersect.

In sum, the **competitive trademark filing landscape is characterized by a mix of industry segments**: supplement and cosmetics companies are extremely active, established pharma firms maintain a baseline of filings, and healthcare service providers and cross-industry entrants (tech, foreign corporates) are increasingly visible. This diversified competition means pharma companies must watch a broader array of players. A surge by a company like BS Suplementos or Boticário in trademark filings can signal an expansion into markets that pharma companies also serve (e.g., nutraceuticals or dermo-cosmetics), potentially intensifying competition in those niches. The **rise of domestic mid-tier pharma (A2F, Blau)** as aggressive filers further indicates that local companies are bolstering their portfolios to challenge larger incumbents. **Competitive dynamics are thus shifting subtly**: where once a handful of big pharma dominated filings, now a wider field of cosmetics, supplement, and health-tech entities are claiming their space, necessitating vigilant monitoring by all incumbents.

Trademark Oppositions & Conflict Watch

Amid the high volume of new filings, **trademark oppositions and legal conflicts remain a critical backdrop**. The alerts data and bulletin review for RPI 2829 indicate that opposition activity continues at roughly the same steady pace observed in prior weeks. There were *no extraordinary spikes in oppositions* in this issue, suggesting a continuation of ongoing disputes rather than a sudden surge of new ones.

In the previous report, we noted around **320 oppositions** concentrated in saturated classes (such as class 5 for pharmaceuticals) and this edition appears to track that baseline

. This steady rate means that while new conflicts do arise, they are largely keeping proportional to the influx of new filings – essentially, **dispute volume is rising in line with filing volume**, with no sign of an out-of-proportion jump.

Notably, **cross-industry oppositions** – a phenomenon where consumer goods giants challenge pharma trademarks – did not present any high-profile new cases in RPI 2829, continuing the trend from the last edition. For instance, we previously highlighted Disney Enterprises as an example of a non-pharma company that has opposed pharma trademarks when names overlap with its famous brands. In this bulletin, Disney did not initiate any major new oppositions against pharma marks. Interestingly, Disney was active on the filing side instead, securing several of its own trademarks (e.g., for entertainment titles like *"Kaa"* and *"Dumbo"*), but these were outside the pharma realm. The absence of new Disney-vs-pharma clashes this week implies that **ongoing cross-industry disputes are still unfolding through legal processes** (from earlier oppositions), but no fresh battles were sparked in this particular issue. Pharma companies should not be complacent, however – the risk of well-known consumer brands policing their names in all classes remains (e.g., if a pharma product name coincides with a famous character or franchise, an opposition could still occur).

Within the pharma sector, the **traditional pattern of companies opposing confusingly similar marks continues**. Leading pharmaceutical firms are known to keep a close watch on new applications that might conflict with their established brands. The current data shows ongoing opposition filings and decisions, though none made headlines as an outlier case in this bulletin. We interpret this as business-as-usual for pharma legal teams: monitoring the RPI for any name that comes too close to theirs and filing oppositions when necessary. This could include, for example, challenges against smaller companies whose new drug or supplement name is deceptively similar to a well-known medication. Such defensive oppositions are a routine part of competitive strategy in the pharma industry

Another area of conflict risk is **generic or descriptive names** for drugs. Regulatory examiners and competitors alike continue to flag trademarks that resemble generic drug names (INNs). In RPI 2829, there were no publicly noted new rejections or oppositions purely on this basis, but the underlying **legal principle**

remains in force: applications that are too close to a common pharmaceutical name will face pushback

. Companies occasionally find their trademark applications opposed or refused if, for instance, the name is essentially the drug's active ingredient or a known generic term. The steady scrutiny by INPI ensures that each new filing is evaluated for distinctiveness – which is a form of conflict prevention at the examination stage.

Enforcement quality also continues to be a theme. We observe that companies are willing to pursue oppositions and even court actions (nullity, appeals) as needed to protect market share.

This edition did not reveal any novel legal battles beyond typical oppositions, but the consistent level of disputes underscores that **oppositions remain a common tool** in the pharma sector's competitive arsenal. In practical terms, this means every significant new product launch by one company could trigger an opposition from a rival if the chosen brand name is even borderline similar to an existing mark. It also means that smaller firms entering the market must be prepared to face challenges from incumbents, especially in those classes (5, 10, 44) that are highly saturated with prior marks.

In summary, the **risk and conflict environment** for pharma trademarks in RPI 2829 is one of **steady, active vigilance**. Companies continue to guard their IP through oppositions at a regular clip, maintaining the pressure on newcomers. While no single conflict dominated this bulletin's narrative, the collective weight of hundreds of small disputes is significant. This steady drumbeat of oppositions suggests that any surge in filings we're seeing (as in 2025's uptick) will likely result in a proportional uptick in disputes down the line

– a reminder that **today's filings are tomorrow's potential conflicts**. Firms should thus keep their watch on the opposition docket as closely as they do on new filings.

M. J. Zanon –IPR Lawyer, Patents, Trademarks, Translations in Brazil
Marcus Julius Zanon
IPR Lawyer, Consultant & Registered Patent Agent
Email: iplawyer@mjzanon.com mjzanon@yahoo.com Website : http://www.mjzanon.com
Linkedin : https://www.linkedin.com/in/mjzanon Twitter: www.twitter.com/mjzanon
Rua Clemente Albini, 51 - Pilarzinho - CEP 82100-500 - Curitiba - Paraná - Brazil
Cell Phone +55 41 991371456

Strategic Recommendations

Given the trends and data above, several **strategic recommendations** emerge for stakeholders in the pharmaceutical and healthcare trademark space:

- **Monitor Broadly and Proactively:** The expanding range of trademark filers – from pharma labs to beauty companies to tech startups – means pharma companies must **cast a wide net in monitoring**. It is advisable to keep an eye not only on direct competitors' filings, but also on cross-industry entrants (e.g. cosmetics, food supplements, tech firms entering health). Utilizing an automated alert system for trademark publications can greatly assist in this vigilance. (For instance, the TWS IP AI tool can send real-time alerts on relevant filings or potential conflicts, which helps IP teams catch threats early.) By monitoring bulletins like RPI 2829 proactively, companies can identify potentially conflicting marks as soon as they are published and take timely action.
- **Act on Oppositions and Defense: Opposition proceedings** remain a cornerstone of competitive strategy in Brazil's pharma sector. Companies should be prepared to **file oppositions or even nullity actions** against new applications that encroach on their brands. This defensive posture can prevent marketplace confusion and safeguard market share. Conversely, firms launching new brands must also **prepare to defend against oppositions**. It is prudent to compile evidence of distinctiveness and prepare arguments (e.g., differences in product scope, stylization, or market) to counter any challenges. Essentially, incorporate opposition response planning into your brand launch timeline. The steady level of disputes means any notable new brand is likely to receive scrutiny; having a legal game plan in advance can make the difference in securing your mark.
- **Ensure Distinctive Branding:** The prevalence of conflicts over **descriptive or generic names** highlights the importance of choosing inherently distinctive trademarks. Pharmaceutical companies should avoid marks that closely resemble INN names or common descriptive terms for the product's function. Not only do such names face possible examiner refusal, they invite oppositions from competitors who can easily argue lack of distinctiveness.
- Invest in creative branding and legal screening early in the naming process. A distinct name reduces the risk of costly disputes down the road. If a less

distinctive name is commercially desired, be ready with robust evidence of acquired distinctiveness and a backup plan.

- **Leverage Portfolio Strategies:** This report's findings suggest many companies file **multiple related trademarks** (series or families). Pharma companies should consider a similar strategy: **secure a "family" of marks** around key products or technology platforms. For example, registering variations and extensions of a core brand (XYZ Plus, XYZ Care, etc.) can preempt competitors from getting too close to your brand identity. This strategy, used by leading companies to cover line extensions and defensive marks, helps guard against brand dilution. However, manage this cost-benefit wisely – focus on strategically important marks (such as those associated with major drug franchises or new therapeutic areas).
- **Adapt to Convergence with Tech:** With technology terms and players increasingly intersecting with healthcare, pharma businesses should **adapt their IP strategy to digital health**. This might mean protecting trademarks not just for drugs or devices, but also for software platforms, mobile apps, AI tools, and telemedicine services that the company offers. If a pharma company is launching a patient app or an AI diagnostic tool, it should file trademarks in the appropriate classes (e.g., class 9 for software, class 42 for IT services) to mirror the tech entrants who are moving into healthcare. Additionally, consider collaborations or **cross-licensing** with tech firms for brand use, as this can sometimes preempt conflicts and open new markets.
- **Keep an Eye on Emerging Markets and Regions:** The data shows growth in filings from regions like Santa Catarina and from sectors like supplements and cosmetics. Strategically, pharma companies may explore **partnerships or acquisitions** in those burgeoning hubs or segments to stay competitive. If SC's biotech startups are filing many trademarks, they could be on the cusp of valuable innovations – engagement there could yield opportunities. Regionally, ensure your own trademark coverage extends to where new competitors are arising; for example, if historically you focused on SP/MG, check that your key brands are also protected against newcomers in SC or GO, etc.
- **Utilize Professional Guidance:** Finally, given the complexity of Brazil's trademark landscape, companies should engage experienced IP counsel for both proactive strategy and reactive enforcement. An IP attorney who actively follows RPI publications can provide early warnings on relevant

filings (as done in this report) and advise on nuanced matters like oppositions, consent agreements, or co-existence strategies if conflicts arise. In a dynamic environment where filings and legal actions are prolific, expert guidance helps in **navigating the regulatory shifts and procedural intricacies** efficiently.

By implementing these strategies, businesses in the pharmaceutical and health sectors can better navigate the competitive trademark environment highlighted in RPI 2829. The goal is to transform the insights from this analysis – trends in filings, conflict patterns, and emerging players – into concrete actions that secure and strengthen your brand's position in the market.

Conclusion: In summary, the Brazilian pharma trademark landscape as of March 2025 is one of high activity and evolving competition. Innovation in branding is evident through diverse new filings, while the guardrails of oppositions and legal enforcement remain firmly in place to manage conflicts. Companies that stay informed (through data-driven alerts and reports like this), adapt to new trends (like tech convergence and wellness branding), and rigorously defend their IP rights will be best positioned to thrive. Intellectual property is a strategic asset in the pharmaceutical industry – and as this report shows, it must be managed with both vigilance and agility.

For further consultation or tailored advice on pharmaceutical trademarks and IP strategy in Brazil, please contact: **M. J. Zanon – Brazilian IP Attorney-At-Law** (Email: iplawyer@mjzanon.com | Website: www.mjzanon.com).

Methodology

Data Collection

- **Source of Data:** The data for this analysis was sourced from the **INPI RPI2829** (Industrial Property Bulletin) Publications, published on **25/03/2025**. The publication provides comprehensive information on trademark applications, including details of new filings, oppositions, and other legal proceedings relevant to trademarks.
- **Data Selection Criteria:**
    - We extracted data on trademark applications and oppositions within the **pharmaceutical sector**, specifically targeting NICE classes relevant to pharmaceuticals and healthcare:
        - **Class 5** – Pharmaceuticals
        - **Class 10** – Medical Devices
        - **Class 42** – Scientific and Technological Services
        - **Class 44** – Medical and Veterinary Services
    - Additionally, we included filings related to health-tech, telemedicine, AI-driven healthcare solutions, and biotech platforms to capture the full competitive landscape in the evolving health and pharmaceutical markets.

Analytical Techniques

- **Data Processing:**
    - The data underwent rigorous cleaning to address inconsistencies (e.g., formatting errors, duplicate entries).
    - We filtered the dataset to isolate filings in the key NICE classes mentioned above.

  - The data was structured to facilitate multi-level analysis across applicants, regions, and trademark types.

- **Competitive Landscape Analysis:**
  - Top filers were identified using aggregate counts and ranked to highlight competitive trends.
  - Filing activity was segmented by region and class to identify sector and geographic dominance.
  - Conflicts were analyzed by grouping trademarks by name and class to detect overlapping or contested filings.
- **Heatmap Creation:**
  - A heatmap was generated using **Python's Matplotlib** and **Seaborn** libraries, with states as rows and NICE classes as columns.
  - The values represent the count of filings and oppositions, color-coded to reflect varying levels of activity.
- **Word Cloud Generation:**
  - A word cloud was created from trademark names using the **WordCloud** library.
  - Larger words reflect higher frequency of occurrence, highlighting dominant branding terms and competitive trends.
- **Additional Visualizations:**
  - Bar graphs and trend analyses were generated to provide a comparative view of trademark filing and opposition activity across states and over time.
  - Top filers were plotted in a bar chart to visualize market concentration and competitive strength.

- Geographic trends were shown in a comparative chart to reflect regional distribution of filings.

Validation and Quality Control

- **Data Integrity Checks:**
  - Rigorous integrity checks were conducted to ensure data completeness and accuracy.
  - Potential misclassifications, empty fields, and anomalies were identified and corrected.
- **Conflict Detection and Verification:**
  - The dataset was checked for identical or similar trademark names within the same NICE class and region to highlight potential conflicts.
  - AI-driven conflict detection methods were employed to identify hidden overlaps and potential litigation risks.
- **Analytical Review:**
  - The analytical processes and outputs were reviewed by both data analysts and legal experts to ensure methodological soundness and accurate interpretation of competitive dynamics.

Reporting Strategy

- **Objective Reporting:**
  - The report provides data-driven, objective insights into trademark filings and competitive trends within the pharmaceutical sector.
  - Analysis is presented without bias, focusing on factual accuracy and market relevance.
- **Actionable Insights:**

  - Each section concludes with strategic recommendations tailored to different stakeholder needs (e.g., pharmaceutical companies, IP attorneys, and investors).
  - Insights are designed to inform business decisions and competitive positioning strategies.

- **Continuous Updates:**
  - The report framework is designed to accommodate periodic updates based on new RPI bulletins.
  - The **TWS IP AI Tool** can be configured to automatically analyze new data and update competitive intelligence reports accordingly.
  - Stakeholders are advised to review updated insights quarterly to track competitive shifts and emerging market opportunities.

This updated methodology reflects an enhanced analytical approach with **AI-assisted insights** and **competitive intelligence** techniques, ensuring the analysis remains current and actionable. Let me know if you'd like to adjust any part of it! 😎

📩 Ready to empower your IP strategies?

Discover how the TWS IP AI Tool can revolutionize your decision-making and streamline trademark approvals.

🔗 Connect with Me:
📞 Cell: +55 41 99137-1456
📧 Email: iplawyer@mjzanon.com | mjzanon@yahoo.com
💼 LinkedIn: Marcus Julius Zanon
🐦 Twitter: @mjzanon

🌐 Website: http://www.mjzanon.com

Member, International Intellectual Property Law Association (IIPLA)

Office Address:
Rua Clemente Albini, 51
Pilarzinho, Curitiba, Paraná, Brazil, CEP 82100-500

Additional Contacts:
WeChat ID: MJZANON-BRAZIL

This newsletter is powered by our advanced Trademark Analysis Tool, providing data-driven insights to help you protect and optimize your brand.